Beta alethine

Drug Profile

Beta alethine

Alternative Names: Alethine beta; Beta LT; Betathine

Latest Information Update: 16 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of New Mexico
  • Developer LifeTime Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma

Highest Development Phases

  • Discontinued Lymphoma; Macroglobulinaemia; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 30 Apr 2002 LifeTime Pharmaceuticals has acquired all the intellectual property covering beta alethine from Dovetail
  • 30 Nov 2001 Phase-I/II in early multiple myeloma and MGUS in USA (unknown route)
  • 31 Aug 2000 Phase-I/II clinical trials for Lymphoma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top